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Diabetogenic Polypeptide From Human Pituitaries Similar 
to That Excreted by Proteinuric Diabetic Patients 
By LAWRENCE H. LOUIS AND JEROME W. CONN 
A polypeptide exhibiting diabetogenic body weight to dogs resulted in significant 
and antiinsulin properties has been iso- intolerance to glucose and resistance to 
lated from human pituitary glands by exogenous insulin 10 and 34 hours 
a procedure slightly modified from that after injection. Comparison of glucose 
with which a similar polypeptide was tolerance tests in the same animals dis- 
previously isolated from the adeno- closes that the diabetogenic potency of 
hypophysis of cattle, sheep and pigs. The the substance from human pituitaries is 
isoelectric point of the compound is ap- much greater than that of human growth 
proximately pH 4.1 which is the same hormone or ovine prolactin. The molecu- 
as that of the compound isolated from lar weight of the substance as determined 
the adenohypophysis of the other three by the dodecyl sulfate-polyacrylamide gel 
species and from urine of patients with electrophoresis method is 20,600. A 
lipoatrophic diabetes and proteinuric dia- modified procedure for the isolation and 
betics without lipoatrophy. Administra- purihcation of the polypeptide has been 
tion of 1 mg polypeptide per kilogram of outlined. 
W E HAVE REPORTED in previous communications the isolation of a diabetogenic polypeptide from the urine of patients with lipoatrophic 
diabetes,l the urine of proteinuric diabetic patients without lipoatrophy,2 and 
the adenohypophysis of beef,” sheep and pigs.4 The peptide from all these 
sources has been shown to induce hyperglycemia and resistance to exogenous 
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Fig. 1 .-Procedure for isolation of diabetogenic polypeptide (human PI) from 
human pituitaries. 
insulin when administered to dogs or humans. Because the compound ob- 
tained from each of the above mentioned sources exhibits similar physicochemi- 
cal and biological properties, it was concluded that the origin of the polypeptide 
found in the urine of diabetic patients is probably the pituitary gland. Since 
this conclusion was based on the isolation of a similar peptide from pituitary 
glands of cattle, sheep and pigs, w it became important to carry out parallel 
studies employing pituitary glands of man. 
The purposes of the present paper are to outline a slightly modified pro- 
cedure for the isolation and purification of the diabetogenic polypeptide from 
human pituitary glands, to demonstrate its antiinsulin and diabetogenic effects 
in dogs, and to compare its diabetogenic potency with that of human growth 
hormone and ovine prolacti,n. 
MATERIALS AND METHODS 
After a 2-yr period a sufficient number of human pituitary glands were collected from 
local hospitals to carry out these studies. After removal the glands were frozen. The active 
peptide was isolated according to the procedure outlined in Fig. 1. Our previously published 
method for the extraction of bovine diabetogenic peptide is also suitable.3 Its isoelectric 
point (approximately pH 4.1) proved to be the same as that of the peptides obtained from 
animal adenohypophysis and from urine of proteinuric diabetic patients. The average yield 
is 0.03-0.04%. This material is designated as human PI. 
The oxycellulose powder (16-22% COOH, Eastman Chemical Products, Inc., Kingsport. 
Tenn.) used in the procedure was kept refrigerated and before being used was washed suc- 
cessively with distilled water, 0.1 N HCl and distilled water. 
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Fig. 2.-Effect of human PI on insulin tolerance in dogs T and 0. 
A Sephadex G-100 superfine descending column (0.9 X 60 cm) was used for the purifica- 
tion of human PI. The gel was equilibrated and eluted with 0.03 N HCI containing 0.2 
M NaCl. Diabetogenic peptide (20 mg) was dissolved in 0.05 N HCl (0.6 ml) and applied 
to the column. The elution rate was 0.3 ml/20 min. The operating pressure was 20 cm. 
Protein was determined by the procedure of Lowry .6 The active polypeptide was recovered 
either by isoelectric point (pH 4.1) precipitation or by dialysis against distilled water. The 
procedure for acrylamide gel electrophoresis has been described previously.% 
Human growth hormone (lot 1-C) was obtained from the National Institute of Arthritis 
and Metabolic Diseases, National Pituitary Agency of the University of Maryland. This 
preparation has a biopotency of 1 I.U. per milligram. The hormone was dissolved in 2 ml 
of distilled water and administered subcutaneously as a single dose. Human growth hormone 
(Raben # 16) has a mean biopotency of 1.1 I.U. per milligram. The protein was dissolved 
in dilute hydrochloric acid and neutralized with 0.05 M NaOH to pH 7.0. Human growth 
hormone (Merck Sharp and Dohme C-1555) was dissolved in 2 ml distilled water and 
neutralized with 0.05 M NaOH to pH 7.0. 
Ovine prolactin (NIH-P-S-7) was obtained from the National Institute of Health, 
Endocrinology Study Section, Bethesda, Md. This preparation has a mean Potency of 24.3 
I.U. per milligram. The hormone was dissolved in 2 ml of distilled water and administered 
subcutaneously as a single dose. 
Four trained normal dogs, two males and two females, were employed for biological 
assay. Maintenance and preparation of dogs for glucose and insulin tolerance tests have 
been previously described.4 The polypeptide was dissolved in 1.5 ml 0.05 N HCl and 
neutralized by dropwise addition of 0.05 N NaOH to pH 6.7-7.0. The solution was ad- 
ministered subcutaneously as a single dose. No untoward effects were observed. Blood 
glucose was determined by the Somogyi-Nelson procedure.6 
Molecular weight estimation was carried out by the dodecyl sulfate-polyacrylamide gel 
electrophoresis procedure of Weber and Osborn. 7 Pure ovalbumin, chymotrypsinogen A, 
ribonuclease A and cytochrome C were used as protein standards. 
RESULTS 
The polypeptide isolated from the human pituitary glands was tested for 
anti-insulin activity in two normal dogs (0 and T). Each animal was given 
a single subcutaneous injection of 1 mg of the polypeptide per kilogram of 
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Fig. 3.-Effect of subcutaneous 
glucose tolerance of normal dog P. 
administration of human PI and bovine PI on 
body weight. Insulin tolerance tests were carried out 10 and 34 hr after poly- 
peptide administration. It is apparent (Fig. 2) that sensitivity to the hypogly- 
cemic effect of exogenous insulin was significantly reduced. Insulin resistance 
was still evident in both animals 34 hr after polypeptide administration. 
The effect on glucose tolerance was studied in dogs P and L. Again a dose 
of 1 mg of polypeptide per kilogram of body weight was employed. Carbo- 
hydrate tolerance was greatly impaired in both animals (Figs. 3A and 4A) at 
10 hr and less so at 34 hr. In dog L, 58 hr after polypeptide administration, 
glucose tolerance had returned to the preinjection level. 
For comparative purposes, the same two animals (dogs P and L) were 
studied using bovine polypeptide. In dog P, two separate experiments with doses 
of 1 mg and 2 mg of bovine PI per kilogram of body weight were carried out with 
an interval of 13 days between them. The results are presented in Fig. 3B and 
3C. One milligram per kilo of the human peptide appears to have induced the 
greatest decrease in glucose tolerance. In dog L, 2 mg/kilo of the bovine pcp- 
tide induced no change in glucose tolerance but the effect of 4 mg/kilo is seen 
in Fig. 4B. While the number of tests is too small to make a meaningful com- 
parison, it appears that in both animals the human peptide induced the greater 
loss of glucose tolerance. 
The effect of human growth hormone on glucose tolerance was also observed 
in dogs L and P. The dose was 0.125-1.0 mg of hormone per kilogram of body 
weight and glucose tolerance test was carried out 10 hr after each injection. 
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Fig. 4.-Effect of subcutaneous administration of human PI, bovine PI, and 
purified diabetogenic polypeptide isolated from urine of diabetic patient C.S. on 
glucose tolerance of normal dog L. 
Table l.-Effect of Human Growth Hormone on Glucose Tolerance 
Dog L, Male, 15.4 kg Body Weight 
Hours after injection F ‘ii 1 1% 
Control 73 87 79 84 
10 (0.125 mg/kg HGH*) 74 86 88 63 
10 (0.25 mg/kg HGH*) 72 123 129 132 
Control 78 93 88 74 
10 (0.5 mg/kg HGH*) 72 122 78 99 
10 (1.0 mg/kg HGH*) 86 126 98 96 
Dog P, Female, 7.8 kg Body Weight 
Control 86 152 186 131 
10 (0.5 mg/kg HGH t) 77 142 162 107 
10 (0.5 mg/kg HGH $) 73 158 167 116 
* NIH-HGH, lot 1-C. 
i NIH-HGH, Raben # 16. 
$ Merck Sharp and Dohme, Lot C-1555. 
2 2% 3 
57 73 83 
69 55 72 
72 77 82 
72 82 80 
69 83 84 
74 81 84 
80 68 75 
79 67 70 
72 65 73 
The results are shown in Table 1. It is clear that at these dose levels no sig- 
nificant change in glucose tolerance was observed in both of the animals. Ovine 
prolactin (0.5 mg/kilo) did not induce any significant change in glucose tolerance 
in dog P, the results are shown in Table 2. In contrast, administration of 1 .O mg/ 
kilo of human PI in dog L induced a great decrease of glucose tolerance (Fig. 
4A). In dog P 0.5 mg/kilo of purified human PI induced significant intolerance 
to glucose. The results are shown in Table 3. However, 0.25 mg/kg body weight 
of purified human PI did not provoke any significant alteration of glucose toler- 
ance in this dog. 
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Table 2.-Effect of Ovine Prolactin on Glucose Tolerance 
_. 




10 (0.5 mg/kg) 
Dog P, Female, 7.8 kg Body Weight 
F ‘/2 1 1% 
72 156 164 92 
64 153 157 86 
80 123 158 134 
2 2% 3 
59 68 66 
58 70 76 
76 69 69 
* NIH-P-S-7. 
Table 3.-Effect of Human PI on Glucose Tolerance 
Dog P, Female, 7.8 kg Body Weight 
Hours after injection 
Human PI 0.5 mg/kg body weight F % 1 1% 2 
Control 66 124 151 118 66 
10 84 135 211 159 96 
34 87 140 222 164 104 
106 66 118 165 162 86 








The effect of a highly purified polypeptide preparation (isoelectric point ap- 
proximately pH 4.1) extracted from the urine of a proteinuric diabetic patient 
(C.S.) was studied on the same animal (dog L). One milligram per kilogram 
was administered subcutaneously as a single dose (Fig. 4C). Its diabetogenic 
potency in this animal is clearly greater than that of the bovine peptide which 
was inactive at 2 mg/kilo. 
Figure 5 shows the Sephadex column chromatography profile of the dia- 
betogenic polypeptide from human pituitary glands. The first peak has no 
diabetogenic effect in dogs. Disc acrylamide gel (7.5%, pH 8.8) electrophoresis 
of the active fraction is shown in Fig. 6. The diabetogenic activity (0.5 mg/ 
kilo) of this fraction (second peak) is shown in Fig. 7. Larger amounts are 
not available for testing. 
Five separate molecular weight determinations of purified human PI by the 
method of Weber and Osborn give the following values: 20,500; 22,600; 19,600; 
21,000 and 19,500. The molecular weight of the peptide as determined by 
this method appears to be approximately 20,600. A typical run is shown in Fig. 
8. 
Fig. S.-Purification of human PI on 
Sephadex G-100 superfine. 
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Fig. 6.-Polyacrylamide gel electro- 
phoresis of purified human PI. Band at 
Bottom of gel represents tracking dye. 
DISCUSSION 
A diabetogenic polypeptide has been isolated from human pituitary glands 
employing a slight modification of the procedure with which a similar poly- 
peptide was previously isolated from adenohypophysis of cattle,3 sheep, and 
pigs.4 The physicochemical properties of the substance isolated from the adeno- 
hypophysis of all four species are similar to those of the peptides extracted from 
the urine of patients with lipoatrophic diabetes and from the urine of pro- 
teinuric diabetic patients without lipoatrophy.2 The isoelectric point of the 
active polypeptide isolated from all these sources is approximately pH 4.1. 
The possibility that the substance might be somatotropin is unlikely since the 
LOUIS AND CONN 
Fig. 7.-Effect of purified human PI 
on glucose tolerance in dog P. 
isoelectric point of human growth hormone is pH 4.9 and all material that pre- 
cipitated at this pH was removed during our isolation procedure. Nevertheless, 
our polypeptide could still be contaminated with growth hormone since the disc 
acrylamide gel electrophoresis pattern indicates a small band before the large 
one. Antihuman growth hormone serum reacts with our substance to about 
10% (performed by Dr. Ralph Knopf of our group) but the possibility that 
the cause of the glucose intolerance might be due to the presence of soma- 
totropin in our preparation is remote since administration of 0.5-l .O mg/kilo 
6 . 
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Fig. 8 .-Molecular weight determina- 
tion of human PI. Four marker proteins 
used were ovalbumin, 45,000; chymo- 
trypsinogen A, 25,000; ribonuclease A, 
13,700; and cytochrome C, 11,700. 
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of human growth hormone does not provoke any significant change in carbo- 
hydrate tolerance in the same animals. Whether our human pituitary diabeto- 
genie polypeptide (human PI) has any growth-promoting activity remains to be 
determined. It should be mentioned, however, that by means of the tibia test, 
our bovine pituitary diabetogenic polypeptide (bovine PI) exhibits no growth 
promoting activity.8 The chance that the peptide might be ACTH is also un- 
likely since the molecular weight of the two compounds are greatly different. 
We have shown previously that bovine PI3 and the diabetogenic polypeptide 
extracted from the urine of patients with lipoatrophic diabetes exhibit no adrenal 
stimulating activity in man .l The possibility that the peptide might be prolactin 
cannot be ruled out completely. In one experiment, ovine prolactin (0.5 mg/ 
kilo) did not induce any significant change in glucose tolerance in the same 
dog (dog P) in which human PI decreased it. By means of the Reece-Turner 
indermal pigeon crop technique, the diabetogenic polypeptide extracted from 
ovine adenohypophysis (ovine PI) has approximately 4 I.U. per milligram of 
prolactin activity.4 The molecular weight of human PI has now been determined 
to be 20,600; that of bovine PI is 26,OOO.lO 
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